Presentation on theme: "1 IRB Review of Device Research and Other Clinical Uses of Devices Marian Serge, R.N. Nurse Consultant Division of Bioresearch Monitoring Office of Compliance,"— Presentation transcript:
1 IRB Review of Device Research and Other Clinical Uses of Devices Marian Serge, R.N. Nurse Consultant Division of Bioresearch Monitoring Office of Compliance, CDRH, FDA (240) 276-0250 Marian.Serge@fda.hhs.gov
2 Disclaimer The contents of this presentation are my own, and do not necessarily reflect the views and/or policies of the Food and Drug Administration or its staff. The Food and Drug Administration will not be bound by any of the comments or information contained in this presentation.
3 Topics Background – FDA’s review IRB Review – Significant Risk Devices – Non-significant Risk Devices – Exempt Devices Humanitarian Use Devices Emergency use Custom Device Compassionate Use IRB and Clinical Investigator Non-compliance
4 Background FDA’s Investigational Device Exemption (IDE) Review Pre-IDE meeting ( sponsor and FDA ) – Protocol design may be decided upon IF IRB makes changes - strongly suggest CDRH input IDE application ( sponsor submits research plans to FDA ) – FDA acknowledges the date it received the IDE – FDA determination within 30 days Approve, approve with modifications, disapprove “Condition of approval letter” – Study may start, while sponsor responds to the conditions
5 IRB review of an IDE study IRBs may review an IDE study before FDA approval but with the following risks: – IRB might review again after FDA’s changes and approval – The investigator might start study before FDA approval Standard practice: IRB review after FDA approval – Ensure IDE application is approved by FDA Ask for a copy of FDA approval, or condition of approval letter Ensure letter states study can start
6 FDA-Regulated Research Sponsor IRB and Institution IRB and Institution Clinical Investigator and Research Team Clinical Investigator and Research Team Human Subject Protection & Data Integrity
8 Significant risk device means an investigational device that presents a potential for serious risk to the health, safety or welfare of a subject and is – an implant; – for use in supporting or sustaining human life; – for substantial importance in diagnosing, curing, mitigating, or treating disease or preventing impairment of health; or – the device study presents serious risk to health, safety, or welfare of a subject
9 Significant Risk Device IRB Initial Review Considerations Initial Review – gathering the information – Protocol, informed consent document, device description, previous research, etc. reviewed at convened meeting – Most IRBs have standard forms for completion by clinical investigators at initial review –
10 Significant Risk Device IRB Initial Review Considerations – More questions to ask: Monitoring plans? How often will the site be monitored? Who will implant/use the device? Who will conduct the informed consent process? Are there subinvestigators – what activities? What are the responsibilities of the research team – research activities; CRF completion; device accountability? What are the Field Clinical Engineer activities?
11 Significant Risk Device IRB Review Considerations During Study Unanticipated adverse device effect – Clinical investigators must make UADE reports to sponsor and IRB within 10 working days IRBs may observe the consent process and research [ 21 CFR 56.109(f)] Review of Amendments/changes Sponsor reports to the IRB at least yearly
12 Significant Risk Device IRB Continuing Review Convened meeting Review protocol, current informed consent, adverse events, sponsor info, etc. Review of IRB forms completed by CI Also ask for monitoring reports, accountability records, and ask who is implanting the device, whether device implanted outside the study, etc.
15 Non-Significant Risk Device FDA is not aware of NSR studies IRB is only oversight body for NSR studies Sponsor will make the initial NSR determination
16 IRB Review Non-Significant Risk Device IRB must determine whether the NSR device research is NSR or SR How to make the determination – Review the SR definition – Review Sponsor’s brief explanation of why the device is not a SR – Review the proposed use of the device – Review the additional procedures - surgical – Ask FDA for assistance: 301-594-1190
17 IRB Review Non-Significant Risk Device IRB determination of whether the NSR device research is NSR or SR – If NSR, IRB may continue their review for implementation at the site. If approved, study is considered to have IDE; it may start; must follow abbreviated requirements at 812. – If SR, IRB reports its determination to the CI and where appropriate the sponsor and wait for the sponsor to obtain an IDE before approving the research study at the site.
18 21 CFR 812.2(b) Non-significant risk device studies Sponsor responsibilities [21CFR 812.2(b)] – Label: “Caution-Investigational device limited by Federal law to investigational use. – Ensure IRB approval after presenting the IRB with explanation of why device is NSR. – Ensures Investigators obtain informed consent – Monitoring – Maintains records: name and use of device; explanation of NSR; name and address of CIs; name and address of each IRB; GMP statement, and adverse effects & complaints
19 Non-significant risk device studies Sponsor responsibilities Sponsor responsibilities Reports to IRBs and FDA: unanticipated AEs; withdrawal of IRB approval; withdrawal of FDA approval; at least yearly submit progress reports; recalls (return, repair, disposal); submit final report w/i 6 mo; lack of informed consent to FDA; and the IRB’s SR determinations to FDA. Ensures CIs maintain records and reports No promotion of the NSR device
20 21 CFR 812.2(b) Non-significant risk device studies Clinical Investigator responsibilities Obtain and document informed consent Report unanticipated adverse device effects to IRB and sponsor in 10 working days Report any information about the research to IRB and FDA upon request
21 Research exempt from 21 CFR 812 but not from parts 50 (consent) & 56 (IRB) Several categories of exempt research – 510(k) devices used according to labeling – If the testing is not for determining safety or effectiveness and subjects not at risk Consumer preference testing Testing of a modification Testing of two devices in commercial distribution – Diagnostic devices, if it meets the following....
22 Research exempt from 21 CFR 812 but not from Parts 50 (consent) and 56 (IRB) Diagnostic devices exempt, if the testing Is non invasive (simple venepuncture is okay) Sampling procedure does not present significant risk Will not introduce energy into the body Is confirmed by another established diagnostic procedure Otherwise the diagnostic study must follow 812
23 Informed consent process Important for device studies – Ensure language understandable – Ensure there is no exculpatory language – Ensure patient given opportunity to consider whether or not to participate – Ensure possibility of coercion or undue influence is minimized – Ensure patient is given adequate opportunity to read it before it is signed and dated – IRB: ask about the process at initial and continuing review
24 IRB Review and Informed Consent FDA has no waiver of informed consent (except for emergency use)
27 What is a Humanitarian Use Device? An HUD is a device that is intended to benefit patients in the treatment or diagnosis of diseases or conditions that affect or are manifested in fewer than 4,000 individuals in the US per year. An HUD is a significant risk device
28 Humanitarian Use Device Humanitarian Device Exemption HUD – Office of Orphan Products Development HDE – Office of Device Evaluation
29 HDE application review by CDRH – Bench and animal testing – Clinical experience: may be data, literature, investigation(s), marketing experience – Approval based on probable benefit outweighs risk of injury from its use (not reasonable assurance of safety and effectiveness – as in PMA approval) – HDE label states “the effectiveness of this device for this use has not been demonstrated” – The HDE allows the HUD to be sold
30 What are the HDE holder responsibilities? (Federal Register) The HDE holder is responsible for ensuring that the HUD is not administered to or implanted in a patient prior to obtaining IRB approval at the health care facility. An HDE holder may wish to enforce this requirement by not shipping the HUD to the facility until it has received confirmation of IRB approval.
31 What are the IRBs responsibilities IRB activities – follow Part 56 – Approval before HUD-HDE administered! – Initial review – convened meeting – Continuing review – Withdrawal of approval
32 Federal Register – IRB review of an HUD-HDE FDA believes that the approval criteria set forth in the IRB regulations can and should be interpreted to include consideration of the patient’s need for the HUD and the likelihood that the device is appropriate for the patient’s condition or disease state. (i.e., No special IRB written procedures are needed to review an HUD – use the approval criteria at 56.111)
33 Federal Register – IRB review of HDE An IRB may approve the use of the HUD – in general, for HUD patients – for groups of patients (with the serious HUD disease or condition) that meet certain criteria – under a treatment protocol for the HUD – on an HUD case by case basis
34 Federal Register – IRB review of HDE An IRB may specify limitations on the use of the HUD based upon – one or more measures of disease progression – prior use and failure of any alternative treatment modalities – reporting requirements to IRB or IRB chair – appropriate follow up precautions and evaluations – any other criteria it determines appropriate
35 Federal Register – IRB review of HDE IRB requirement to withdraw approval – Failure to follow IRB or FDA requirements – Unexpected serious harm to subjects
36 What are physician responsibilities? Physician and Institution Activities Report serious adverse events using Medical Device Reporting system 21 CFR 812 Subpart H Information to Patients – Regulations do not require informed consent – IRB and Institution may require consent – Most HUDs have information for patients
37 Humanitarian Use Device Research and off label use Research – If safety and effectiveness data are being collected on the exact use described in approved labeling – IDE may not needed – If research is intended to prove safety or effectiveness for a new use – IDE needed Off label use of HUD – FDA recommends compassionate use provision, which includes prior FDA and IRB concurrence before use.
40 Emergency Use of unapproved device Points for IRBs to Remember Unapproved device (usually under IDE) – Either for new use or – by a physician not part of the research study Physician must determine: – Life-threatening situation or serious disease/condition – No other treatment available – Used once; if potential for more uses -- IDE required and IRB review
41 Emergency Use of unapproved device FDA does not have to concur before it is used. Physician makes report to the IRB and sponsor within 5 working days after use – Uninvolved physician’s assessment – Informed consent (if no consent - next slide) – Institutional clearance, if required – IRB chairperson’s concurrence (if time) – Authorization from the sponsor (if under an IDE)
42 Emergency Use and NO Informed Consent - 21 CFR 56.23 What are HSP requirements if NO consent? – Physician and an uninvolved physician certify that The patient has life-threatening situation Patient is unable to communicate Time is not sufficient to obtain consent from patient or LAR No alternative method of approved or generally recognized therapy that provides likelihood of saving the life – If time not sufficient to find uninvolved physician, then Physician must make above determinations
45 Custom Device All of the following criteria must be met: 1) Necessarily deviates from performance standard or PMA requirements 2) Not generally available in finished form for purchase or dispensing upon prescription 3) Not offered through labeling or advertising 4) Not generally used by other physicians, dentists 5) Specific patient form (the device is formed to the individual patient’s physiological needs) or special needs of a practioner
46 Custom Device IRB Awareness Rule of thumb – Device is only available through special order for an individual patient – Physician requests special design from manufacturer for unique situation – Patient’s name on manufacturer’s order form – Tools for use by specific physician or dentist in medical practice Used by physicians or dentists No IRB review is required. No IDE needed. Institutional policy may require IRB review Report misuse to FDA at 240-276-0125
47 Three Examples when a device was NOT a Custom Device Hydrocephalic shunts made of some other material than silicone because patients allergic to silicone. (IDE needed) Cranial helmets for miss-shaped new-born heads. The helmets were shaped or sized i.e. “fitted” for each subject. (IDE needed) Thoracic Aortic Aneurysm graft ordered individually for each patient (IDE needed)
50 Compassionate Use Compassionate use – Single patient or small group – Serious disease or condition – No alternative available
51 Compassionate Use Physician duties - guidance – Obtain FDA concurrence of the compassionate use before it is used (FDA reviews the sponsor’s protocol or IDE supplement) – Obtain IRB chair’s concurrence and follow IRB procedures – Monitors the patient – Report adverse events to IRB – Follow-up report to sponsor (sponsor reports to FDA) Summary information about patient outcomes
52 Compassionate Use and Patient Protection Measures Guidance Physician obtains uninvolved physician’s assessment of compassionate use Physician obtains IRB chair concurrence – (chair should ask whether FDA concurred) Institutional clearance Physician provides the patient with info and obtains consent for use Physician monitors for problems Physician makes a report
55 To Improve compliance institutions should: Provide training to IRB members & staff Provide training to clinical investigators Implement a quality assurance program Correct & prevent problems before they jeopardize subject safety and the institution’s reputation Focus institutional culture on ethics and good clinical research practices
56 Investigator Deficiencies Fiscal Years 1998 - 2005 19981999200020012002200320042005 Failure to follow investigational plan/regs 32%46%47%44% 51%54%50% Protocol deviations 21%8%26%40%20%38%16%9% Inadequate subject protection/IC 24%19%21%28%21% 24%29% Inadequate device accountability 17% 21%27%26%18%14%7% Lack of FDA &/or IRB approval 11%9%11%5%8%13% 10%
57 Areas where clinical investigators or research team did not comply.... Did not randomize subjects; put all subjects on the investigational device Implanted a patient not in the research study Implanted a “custom” device by requesting it on a “prescription pad” Failed to obtain IRB approval for modifications or amendments in protocol & IC Enrolled subjects who did not meet eligibility criteria
58 Areas where clinical investigators or research team did not comply.... Failed to report unanticipated adverse device effects. Failed to complete CRFs, AE forms, and device accountability records. Failed to include all basic elements in the informed consent document. Failed to ensure completion of all protocol required tests (i.e., 6-month angiograms). Started research study before IRB approval.
59 Areas where clinical investigators or research team did not comply.... Unapproved device implanted without an IDE. CI failed to sign Investigator Agreement. CI refused to give financial information to sponsor. Patients did not sign an informed consent document. Patients signed an informed consent from another hospital IRB.
60 Areas where clinical investigators or research team did not comply.... Patients signed an old version of Informed Consent document Clinical Investigator did not maintain correspondence from IRB No documentation about receipt of devices or distribution to subjects Lost devices